Bafna PharmaceuticalsNSE:BAFNAPH -2.00%60 Return-on-Tangible-Equity is 11.44% as of Mar. 2026, which is 65% above its 10-year median of 6.93. GuruFocus rates NSE:BAFNAPH with a GF Score™ of 60/100 and a GF Value™ of ₹90.74 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 898 Drug Manufacturers companies, Bafna Pharmaceuticals ranks better than 62.81% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Bafna Pharmaceuticals's annualized net income for the quarter that ended in Mar. 2026 was ₹110 Mil. Bafna Pharmaceuticals's average shareholder tangible equity for the quarter that ended in Mar. 2026 was ₹961 Mil. Therefore, Bafna Pharmaceuticals's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 11.44%.
The historical rank and industry rank for Bafna Pharmaceuticals's Return-on-Tangible-Equity or its related term are showing as below:
NSE:BAFNAPH'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -66.31 Med: 6.93 Max: 16.93
Current: 12.23
During the past 13 years, Bafna Pharmaceuticals's highest Return-on-Tangible-Equity was 16.93%. The lowest was -66.31%. And the median was 6.93%.
NSE:BAFNAPH's Return-on-Tangible-Equity is ranked better than 62.81% of 898
companies
in the Drug Manufacturers industry
Industry Median: 7.88
vs NSE:BAFNAPH: 12.23
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Bafna Pharmaceuticals Return-on-Tangible-Equity Related Terms
Bafna Pharmaceuticals Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Bafna Pharmaceuticals's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:BAFNAPH vs ZTS, UTHR: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Bafna Pharmaceuticals's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bafna Pharmaceuticals Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bafna Pharmaceuticals's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Bafna Pharmaceuticals's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 11.44% mean?
Bafna Pharmaceuticals (NSE:BAFNAPH) has a Return-on-Tangible-Equity of 11.44% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Bafna Pharmaceuticals and its competitors. This is 65% above median its historical median of 6.93. According to the industry distribution chart, Bafna Pharmaceuticals ranks #334 out of 898 companies in the Drug Manufacturers industry, placing it in the top 37.2%.
Is Bafna Pharmaceuticals' Return-on-Tangible-Equity too high?
Bafna Pharmaceuticals' current Return-on-Tangible-Equity of 11.44% is 65% above median its 10-year median of 6.93. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.88. Bafna Pharmaceuticals' value of 11.44% is 45.2% above this industry median. Based on the distribution chart, Bafna Pharmaceuticals ranks #334 out of 898 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Bafna Pharmaceuticals has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bafna Pharmaceuticals' Return-on-Tangible-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Bafna Pharmaceuticals ranks #334 out of 898 companies for Return-on-Tangible-Equity. This puts Bafna Pharmaceuticals in the upper half of its industry. The industry median Return-on-Tangible-Equity is 7.88. Bafna Pharmaceuticals' value of 11.44% is 45.2% above this benchmark. While the company's 10-year median is 6.93 vs. the industry median of 7.88, Bafna Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.88, based on 898 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bafna Pharmaceuticals's current Return-on-Tangible-Equity of 11.44% is 45.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Bafna Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bafna Pharmaceuticals's current Return-on-Tangible-Equity is 11.44%, which is 65% above median its own 10-year median of 6.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bafna Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Bafna Pharmaceuticals (NSE:BAFNAPH) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹90.74, compared to a current price of ₹216.45 — trading 138.5% above its estimated fair value. The current Return-on-Tangible-Equity is 11.44%, which is 65% above median its 10-year median of 6.93 and 45.2% above the Drug Manufacturers industry median of 7.88. Bafna Pharmaceuticals' overall GF Score™ is 60/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Bafna Pharmaceuticals (NSE:BAFNAPH), the current Return-on-Tangible-Equity is 11.44% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bafna Pharmaceuticals (NSE:BAFNAPH) Overvalued in 2026?
Based on GuruFocus' analysis, Bafna Pharmaceuticals stock appears to be overvalued.
The current stock price of ₹216.45 is trading 138.5% above its estimated GF Value™ of ₹90.74.
GuruFocus considers Bafna Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for NSE:BAFNAPH:
Return-on-Tangible-Equity: 11.44% (65% above median its 10-year median of 6.93)
GF Value™: ₹90.74 vs. price of ₹216.45 (138.5% above fair value)
Industry Position: 45.2% above the Drug Manufacturers median (#334 of 898)
No single metric tells the full story. See the NSE:BAFNAPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bafna Pharmaceuticals Ltd is an Indian pharmaceutical company mainly offering Contract Research and Manufacturing (CRAMS), Technology Transfers, Formulation, and Analytical Development services. It is engaged in the business of manufacturing finished pharmaceutical formulations, specializing in non-betalactam solid oral dosage forms, besides other emerging and potential products and forms in various therapeutic areas such as cardiology, lifestyle and potent drugs, and pain management. The company delivers generic pharmaceutical products for the UK, Australia, the EU, and emerging markets. In addition, it has launched its own brands in Sri Lanka, the Philippines, Tanzania, and Nigeria, offering products for some high-demand therapies like diabetes, cardiovascular, and oncology.
60GF Score
Get the complete analysis for NSE:BAFNAPH
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:BAFNAPH has been successfully added to your 
